Hosted on MSN6mon
Apellis Pharmaceuticals declines afters CHMP's third negative opinion on Syfovre
European regulators on Friday upheld its negative opinion on Apellis Pharmaceuticals ... This latest ruling follows two previous rejections by the CHMP earlier this year regarding the drug ...
Hosted on MSN9d
Orphelia explores avenues for liquid neuroblastoma med after EU CHMP rejection
Orphelia Pharma is exploring alternative regulatory pathways for Kizfizo (temozolomide) following a negative opinion from the ...
pharmaphorum5y
CHMP says no to Amgen’s osteoporosis drug Evenity
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has decided it cannot approve Evenity (romosozumab), issuing a negative opinion on the drug for the treatment of severe ...
Nasdaq21d
The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU
STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of ...